Gilead Sciences (NASDAQ:GILD) Price Target Raised to $126.00

Gilead Sciences (NASDAQ:GILD) had its price objective raised by Royal Bank Of Canada from $123.00 to $126.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday. HSBC boosted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Truist Financial increased their target price on Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $159.26.

Gilead Sciences Trading Up 2.8%

Shares of GILD stock opened at $151.17 on Thursday. The stock has a market cap of $187.44 billion, a price-to-earnings ratio of -56.62 and a beta of 0.31. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences has a fifty-two week low of $114.02 and a fifty-two week high of $157.29. The firm’s 50 day moving average price is $145.13 and its two-hundred day moving average price is $136.72.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts anticipate that Gilead Sciences will post -0.47 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were given a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is presently -122.85%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the completion of the sale, the chief financial officer directly owned 164,096 shares of the company’s stock, valued at $23,841,507.84. The trade was a 1.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the sale, the director owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 105,000 shares of company stock worth $14,940,540. Company insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently made changes to their positions in GILD. Davidson Trust Co. grew its position in shares of Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 74 shares in the last quarter. Grove Bank & Trust raised its position in shares of Gilead Sciences by 1.2% in the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after buying an additional 74 shares in the last quarter. Financial Connections Group Inc. raised its position in shares of Gilead Sciences by 30.2% in the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 76 shares in the last quarter. Wilkerson Advisory Group LLC boosted its stake in Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 78 shares during the period. Finally, Balboa Wealth Partners boosted its stake in Gilead Sciences by 2.7% during the first quarter. Balboa Wealth Partners now owns 3,057 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 79 shares during the period. 83.67% of the stock is currently owned by institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst support remains broadly favorable. JPMorgan said Gilead’s stock price is expected to rise, while Truist Financial raised its price target. Morgan Stanley also maintained a buy rating, despite lowering its expectations for the shares. JPMorgan analyst expects Gilead stock to rise Truist raises Gilead price target Morgan Stanley buy rating
• Positive Sentiment: Cantor Fitzgerald reaffirmed its overweight rating and set a $155 price target, implying limited additional upside but reinforcing the view that Gilead remains attractive relative to the broader sector.
• Positive Sentiment: Gilead signed a five-year DevOps agreement with Cognizant to improve technology and operational processes. Separately, its oncology collaboration with Nurix was extended by two years, preserving the potential for milestone payments and royalties tied to future therapies. Gilead Cognizant agreement Gilead Nurix collaboration extension
• Neutral Sentiment: The reported October short-interest figure is zero shares, producing a zero-day short-interest ratio. This unusually low reading may reflect a reporting or data issue rather than a meaningful change in investor positioning.
• Negative Sentiment: RBC raised its target from $123 to $126 but retained a sector-perform rating; the target remains materially below the current share price. Morgan Stanley’s lower expectations and modest after-hours weakness also highlight near-term valuation risk. RBC Gilead price target

About Gilead Sciences

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.